Auvi Labs Raises $101,000 Seed Funding to Advance Wearable Dialysis Access Monitoring Technology
Auvi Labs, a Chicago-based medical technology startup developing a wearable system to monitor dialysis access and detect early signs of access dysfunction, has secured $101,000 in seed funding from early-stage investors to advance its prototype and accelerate research and development efforts. The capital infusion represents a key milestone for the company as it works to bring its continuous monitoring solution, often described as a “Dexcom for dialysis access,” closer to clinical validation and eventual commercialization.
Founded in 2024, Auvi Labs is focused on addressing a persistent challenge in hemodialysis care: the high rate of arteriovenous (AV) fistula failure that frequently goes undetected until serious complications arise. The company’s flagship product, the Beacon, is a non-invasive wearable sensor that continuously monitors vascular access sites for early signs of stenosis and thrombosis, enabling clinicians and patients to intervene earlier and reduce the risk of emergency procedures.
The seed round included backing from Illinois Ventures, a venture capital firm that invests in high-potential startups emerging from the University of Illinois ecosystem and the broader Midwest innovation landscape. The firm’s participation signals confidence in Auvi Labs’ technology and its potential to address unmet needs in the dialysis access monitoring market.
According to the company, the newly raised funds will primarily support further development of the Beacon device and its underlying technology. This includes refining sensor performance, enhancing software and analytics capabilities, and expanding the engineering and clinical expertise needed to move the product toward real-world readiness. Strengthening the platform’s technical foundation is critical to ensuring accuracy, reliability, and usability in clinical settings.
A portion of the seed funding is also expected to be allocated toward early product validation and preparatory work related to regulatory pathways. By gathering initial performance data and feedback from clinicians and patients, Auvi Labs aims to build the evidence base needed for larger studies and subsequent regulatory engagement. These steps are intended to position the company for future fundraising rounds that can support broader trials and eventual commercialization.
Auvi Labs’ founding team brings together backgrounds in engineering, healthcare and clinical practice, reflecting the interdisciplinary nature of the problem it is attempting to solve. Dialysis access complications remain a major cause of hospitalization and increased healthcare costs for patients with end-stage kidney disease. Continuous, non-invasive monitoring has the potential to shift care from reactive to proactive, improving outcomes while reducing the burden on healthcare systems.
The company’s seed funding comes amid growing investor interest in health technology solutions that emphasize early detection, remote monitoring and data-driven care. Wearable medical devices and predictive analytics tools have gained traction as healthcare providers seek ways to improve patient outcomes while managing costs. Auvi Labs’ approach aligns with these trends by offering continuous monitoring paired with actionable insights for clinicians.
Support from regional venture firms such as Illinois Ventures also highlights the role of local innovation ecosystems in nurturing early-stage medical technology startups. Beyond capital, such investors often provide strategic guidance, industry connections and access to research and commercialization resources, all of which can be critical for young companies navigating the complex healthcare landscape.
Looking ahead, Auvi Labs plans to continue refining its technology while engaging with clinical partners to test and validate the Beacon wearable in real-world environments. Feedback from these early engagements is expected to inform product design and help demonstrate value to both patients and providers. The company also intends to explore partnerships that could support manufacturing, distribution and integration into existing dialysis care workflows.
As healthcare continues to embrace remote monitoring and preventative care models, Auvi Labs is positioning itself to play a role in redefining how dialysis access is managed. The seed funding round provides the financial foundation for the company’s next phase of development, bringing it closer to its goal of improving patient outcomes through continuous, proactive monitoring of vascular access sites.
